Bladder Cancer

20201,715 citationsReview

Authors

Andrew T. Lenis · University of California, Los Angeles

Patrick M. Lec · University of California, Los Angeles

MSHS MD · University of California, Los Angeles

Abstract

Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 324, Issue 19, pp. 1980-1980

DOI: 10.1001/jama.2020.17598

Field-Weighted Citation Impact: 204.49